Novartis operates in more than 30 production sites worldwide. With the spin-off of our Sandoz generics and biosimilars business, our sites are now fully focused on producing innovative medicines across our priority technology platforms. Overall, we manufactured approximately 19.8 billion treatments in 2023, ensuring a continuous and reliable supply of our medicines to patients.
Shanelle Gabriel spending time with her father in New York

Transforming manufacturing

The Novartis in Society Integrated Report 2023 describes how our manufacturing operations are evolving as we embrace operational excellence.

Our leadership

Steffen Lang, Ph.D., President, Operations
President, Operations
Steffen Lang, Ph.D.


Quality is a key priority in every aspect of our work. Our patients are relying on us to deliver the highest quality standards, and we are committed to living up to their expectations.

Learn More